This is an old revision of this page, as edited by 81.99.74.135(talk) at 05:05, 19 August 2018(Set appropriate rings as aromatic). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 05:05, 19 August 2018 by 81.99.74.135(talk)(Set appropriate rings as aromatic)
ROD-188 is a sedative drug that was structurally derived from the GABAAantagonistbicuculline by a team at Roche.[1] Unlike bicuculline, ROD-188 acts as an agonist at GABAA receptors, being a positive allosteric modulator acting at a novel binding site distinct from those of benzodiazepines, barbiturates or muscimol, with its strongest effect produced at the α6β2γ2 subtype of the GABAA receptor.[2] ROD-188 is one of a number of related compounds acting at this novel modulatory site, some of which also act at benzodiazepine receptors.[3]
^US Patent 6649626 N-substituted 1-(lactone) isoquinolones for treating nervous disorders
^Thomet U, Baur R, Razet R, Dodd RH, Furtmüller R, Sieghart W, Sigel E. A novel positive allosteric modulator of the GABA(A) receptor: the action of (+)-ROD188. British Journal of Pharmacology. 2000 Oct;131(4):843-50. PMID11030736
^Sigel E, Baur R, Furtmueller R, Razet R, Dodd RH, Sieghart W. Differential cross talk of ROD compounds with the benzodiazepine binding site. Molecular Pharmacology. 2001 Jun;59(6):1470-7. PMID11353808
